News
ARVN
7.58
+6.91%
0.49
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
NASDAQ · 22h ago
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Seeking Alpha · 1d ago
Weekly Report: what happened at ARVN last week (0601-0605)?
Weekly Report · 5d ago
Arvinas joins MJFF-backed PPMI study to support development of LRRK2 degrader ARV-102 for Parkinson’s
PUBT · 06/04 12:06
ARVINAS JOINS THE MICHAEL J. FOX FOUNDATION’S LITE AND PPMI PROGRAMS TO ADVANCE NEW THERAPIES TARGETING LRRK2 FOR PARKINSON’S DISEASE
Reuters · 06/04 12:00
Arvinas Price Target Maintained With a $18.00/Share by Stephens & Co.
Dow Jones · 06/03 12:35
Stephens & Co. Reiterates Overweight on Arvinas, Maintains $18 Price Target
Benzinga · 06/03 12:24
Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)
TipRanks · 06/03 11:40
Arvinas Holding Company (ARVN) Gets a Buy from Barclays
TipRanks · 06/03 08:17
Arvinas Reprioritizes Pipeline, Out-Licenses ARV-806 Development
TipRanks · 06/02 22:14
Arvinas Announces Re-Prioritization Of Portfolio Following Strategic Review; Plans To Complete Phase 1 Monotherapy Dose Escalation Trial And Share Data In 2026; Plans To Seek Out-Licensing Agreement For Additional Clinical Trials Of ARV-806; Expects Cash Position As Of March 31, 2026 To Fund Operations Into Second Half Of 2028
Benzinga · 06/02 20:47
ARVINAS - EXPECTS CASH POSITION AS OF MARCH 31, 2026 TO FUND OPERATIONS INTO SECOND HALF OF 2028 - SEC FILING
Reuters · 06/02 20:40
Weekly Report: what happened at ARVN last week (0525-0529)?
Weekly Report · 06/01 09:20
Arvinas to present at Jefferies Global Healthcare Conference fireside chat
PUBT · 05/29 20:01
Arvinas to Present at Jefferies Global Healthcare Conference
Barchart · 05/29 15:01
Weekly Report: what happened at ARVN last week (0518-0522)?
Weekly Report · 05/25 09:21
Top Arvinas Executive Makes Notable Move With Latest Stock Sale
TipRanks · 05/23 02:12
Citizens biotech analysts hold a dinnermeeting at ASCO
TipRanks · 05/22 19:20
Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)
TipRanks · 05/22 14:20
Wells Fargo Remains a Buy on Arvinas Holding Company (ARVN)
TipRanks · 05/22 11:39
More
Webull provides a variety of real-time ARVN stock news. You can receive the latest news about Arvinas through multiple platforms. This information may help you make smarter investment decisions.
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393, ARV-102, ARV-80, and ARV-027. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC to degrade BCL6, a transcriptional repressor and a regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.